Novartis to acquire The Medicines Company for $9.7bn with eye on inclisiran
Novartis acquisition of The Medicines Company : Swiss drugmaker Novartis signed a deal worth $9.7 billion to acquire US biopharma company The Medicines Company, as ... Read More
Novartis bags Adakveo FDA approval to reduce VOCs in sickle cell disease
Adakveo FDA approval : Swiss drugmaker Novartis has bagged approval for Adakveo (crizanlizumab-tmca) from the US Food and Drug Administration (FDA) for its use in ... Read More
Novartis’ Sandoz to acquire Aspen’s Japanese pharma business
Sandoz, the generic drug business of Novartis has agreed to acquire the Japanese business of Aspen Global Incorporated (AGI), a fully owned subsidiary of Aspen ... Read More
Novartis bags Beovu FDA approval for wet AMD
Beovu FDA approval for wet AMD : Swiss pharma giant Novartis has been given approval from the US Food and Drug Administration (FDA) for Beovu ... Read More
Novartis to acquire IFM Tre with eye on immunomodulatory drugs
Novartis acquisition of IFM Tre : Novartis has signed a deal worth up to $1.575 billion to acquire US biopharma company IFM Tre from IFM ... Read More
Novartis wraps up $2.1bn acquisition of US biopharma company Endocyte
Pharma acquisition news : Swiss pharma giant Novartis has wrapped up its previously announced acquisition of US biopharma company Endocyte in a deal worth around ... Read More
Novartis’ Kisqali plus endocrine therapy shows significant PFS benefits in advanced breast cancer trials
Swiss pharmaceutical giant Novartis has announced that its breast cancer drug, Kisqali (ribociclib), when used in combination with endocrine therapy, has demonstrated substantial efficacy in ... Read More
Novartis bags Gilenya EC approval for multiple sclerosis in young patients
Gilenya EC approval : The European Commission (EC) has expanded the approval of Novartis multiple sclerosis drug Gilenya (fingolimod) to include the treatment of both ... Read More
Spark Therapeutics bags Luxturna EU approval for inherited retinal disease
Luxturna EU approval for inherited retinal disease : Pennsylvania-based Spark Therapeutics has bagged the European Commission’s (EC) approval for its gene therapy Luxturna (voretigene neparvovec) ... Read More
Novartis’ Promacta approved by FDA for first-line treatment of severe aplastic anemia
The U.S. Food and Drug Administration (FDA) has granted an expanded indication for Novartis’ Promacta (eltrombopag), approving it for use in the first-line treatment of ... Read More